Argo Biopharma’s RNAi therapy targets Lp(a): What Phase 2b with Novartis could prove
Novartis advances Argo Biopharma’s BW-20829 into Phase 2b to target lipoprotein(a). Explore what this means for RNAi adoption in cardiovascular therapeutics.
Pharma & Biotech